Hereditary Leiomyomatosis and Renal Cell Cancer - 2 Studies Found

Recruiting : A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
:
  • HLRCC
  • Metastatic Papillary RCC

: 2010-05-25
:
  • Drug: Bevacizumab Commercially
Completed : Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin
:
  • Cutaneous Leiomyomas
  • Hereditary Leiomyomatosis and Renal Cell Cancer : 2009-09-03
    :
    • Biological: Botulinum toxin type A